Quest Diagnostics rises after Q3 profit beats estimates

Quest Diagnostics

21/10/2025 12:06

** Shares of laboratory operator Quest Diagnostics DGX.N rise 2.7% to $195.50 premarket

** Co reports Q3 adj. profit of $2.6/shr vs analysts' average estimate of $2.5/shr - data compiled by LSEG

** Co's quarterly revenue of $2.82 billion beats expectation of $2.74 billion

** DGX raises 2025 forecast; now sees adj. EPS of $9.76–$9.84 vs prior $9.63–$9.83

** "Strong demand for our clinical solutions and diligent execution of our strategy," CEO Jim Davis said

** Up to last close, stock up ~26% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))